# Seasonal Outbreak of Influenza A virus Infection in Pediatric Age Groups During 2004-2005 in South of Iran

A. Moattari, M.R. Kadivar,<sup>1</sup> T. Mokhtari Azad<sup>2</sup>

## Abstract

**Background:** The pandemic and regional influenza outbreaks resulting from antigenic variation of influenza viruses have been the subject of numerous studies which are crucial to the preparation of the vaccine. Frequent global winter outbreaks of influenza viruses require a constant surveillance of emerging influenza variants in order to develop efficient influenza vaccine.

**Methods:** This study was conducted from December 2004 to March 2005, during an outbreak of influenza in 300 children of one to 15-year-old. MDCK cells grown in microwell plates inoculated with pharyngeal swabs. Hemagglutination (HA) of guinea pig erythrocytes by viral isolates was used for initial screening of influenza viruses. The final viral identification was performed by HA inhibition test using reference antisera prepared against WHO reference antigens.

**Results:** Based on the results of HA tests with culture fluid of MDCK inoculated with 300 pharyngeal swabs, 31 (10.3%) of the specimens were suspected to contain influenza viruses of which 10 proved to be either  $A/H_1N_1$  or  $A/H_3N_2$  subtypes. by reacting against aforementioned antisera in HA inhibition test.  $H_3N_2$  subtype prevailed until January 2005 and mostly affected children of younger age, whereas viruses emerging subsequently were only of  $H_1N_1$  subtype and predominantly isolated from children of older age.

**Conclusion:**  $A/H_3N_2$  isolate appears to be antigenically different from corresponding reference antigen. This is evident by a 16-fold reduction in antibody titer by using reference antiserum against  $A/H_3N_2$  Isolate (1:8), as compared to that of reference antigen antibody (1:128).

Iran J Med Sci 2006; 31(3): 131-134.

**Keywords** • Human influenza • vaccine • H3N2 • H1N1 • pediatric

## Introduction

eriodical influenza outbreaks prevail during winter months, mostly in January to March each year and simultaneous with other respiratory infections of viral origin.<sup>1</sup> Epidemiological and virological surveillance of influenza are reported through numerous studies carried out across

Department of Bacteriology and Virology, School of Medicine, <sup>1</sup>Department of Pediatric, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran. <sup>2</sup>Department of Virology, School of Hygiene, Tehran University of Medical Sciences, Tehran, Iran.

#### Correspondence:

Afagh Moattari PhD, Department of Bacteriology and Virology, Shiraz University of Medical Sciences, School of Medicine, Shiraz, Iran. **Tel/Fax: +**98 711 2304356 **E-mail:** moattaria@sums.ac.ir diverse geographic regions.<sup>2-5</sup> Influenza illness is characterized by fever, chills, headache, muscle aches, cough, congestion, sore throat and malaise with bronchitis which commonly occur in small children who are potential sources of infecting adults. The mutability of influenza A and B viruses stipulates the need for a constant surveillance of emergent strains, a process fundamental to the development and reappraisal of current influenza vaccines.<sup>6</sup> The present study describes the first attempt to isolate and identify influenza viruses from children during December 2004 to March 2005 in Shiraz, south Iran.

## **Material and Methods**

#### Specimen collection and processing

This study was conducted from December 2004 to March 2005. Pharyngeal swabs were collected from 300 patients of 1-15-years old by sterile cotton-tipped sticks. They were then placed in sterile screw-capped containers with Eagle's minimum essential medium and transported, under refrigeration, to the laboratory where they were gently agitated and extracted for further processing. The extracts were kept at -70°C until used.

## Cell culture

Madin-Darby canine kidney (MDCK) cells were supplied by central influenza reference laboratory in Tehran affiliated to the World Health Organization (WHO). These cells were used after three passages in Dulbecco's minimum essential medium (DMEM, Sigma; USA). The medium was supplemented with 7% (V/V) fetal bovine serum (GIBCO; USA), 100 unit/ml penicillin G and 100µg streptomycin /ml.

## Viral isolation

Cells grown for 48h in 24 microwell plates were used for inoculation of clinical specimens. This was achieved by discarding the growth medium and rinsing the monolayers with 2 ml phosphate buffered saline (PBS). Each monolayer was then inoculated with 200µl of the sample and incubated at 34°C for 60 min. followed by addition of 1 ml serum-free DMEM containing 2 µg/ml of trypsin (DIFCO). The plates were incubated at 34°C in 5% CO<sub>2</sub> for 96 hr for cytopathic effect (CPE) to develop, if cell monolayers had been inoculated with virus positive specimens. The ability of influenza viruses to hemagglutinate was determined by treating monolayers with 0.5% suspension of guinea pig erythrocytes in PBS at 4°C for 2 hr. This tentative viral identification was subsequently confirmed by hemagglutination inhibition (HI) test with reference antisera.

## HI Test

A modification of HI test described elsewhere,<sup>7</sup> was used in the present study. Briefly, serial two-fold dilutions of each reference antiserum in 25 $\mu$ l of PBS were prepared in 96 microwell plates. An aliquot of 25 $\mu$ l containing four HA units of the antigen under study was then added to each microwell. The contents of microwells were mixed by gentle agitation and held at room temperature for one hr, when 50 $\mu$ l of a 0.3% suspension of guinea pig erythrocytes was added to each microwell. The plates then shaken gently and the results recorded two hrs after of incubation at 4°C.

# Serotyping

The identification of the types and subtypes of viral isolates was achieved using HI test and reference antisera. These comprised antisera against A/NewCaledonia/20/99(H<sub>1</sub>N<sub>1</sub>)-Like, A/Moscow/10/99(H<sub>3</sub>N<sub>2</sub>)-Like, B/Sichuan/ 330/2001/-Like and B/Hong Kong/330/200/-Like Antigens.<sup>7</sup>

# Results

This study was conducted from December 2004 to March 2005. Of 300 pharyngeal specimens inoculated into MDCK monolayers, 31 (10.3%) agglutinated guinea pig erythrocytes and were suspected of containing influenza viruses. Table 1 shows reciprocal hemagglutination-inhibition antibody titers against four reference influenza virus antigens using homologous and heterologous reference antisera. Initially, 14 of 31 tentative influenza virus isolates were examined by HI test for their inhibition by 4 reference typing antisera. As a result, 10 isolates proved to be influenza viruses of which 4 were  $H_1N_1$  subtype and  $6 H_3N_2$ .

**Table 1:** Reciprocal Hemagglutination-inhibition antibody

 titers of four reference influenza virus antigens against

 homologous and heterologous reference antisera

Reference	Reference Antisera					
Antigens	Α	В	С	D		
A	128	8	<1	<1		
В	<1	128	<1	<1		
С	<1	<1	128	8		
D	<1	<1	4	128		

A= A/NewCaledonia/20/99 (H<sub>1</sub>N<sub>1</sub>)-like;

B= A/Moscow 10/99 (H<sub>3</sub>N<sub>2</sub>);

C= B/Sichuan 330/2001-like;

D= B/Hong Kong 330/2001-like

 $H_3N_2$  subtype prevailed until January 2005 and mostly affected children of younger age. The subtype emerging from January 2005 until February 2005 was only  $H_1N_1$  and predominantly

Table 2: Reciprocal Hemagolutination-inhibition antibo	dv titers of A/ H <sub>1</sub> N <sub>1</sub> A/ H <sub>3</sub> N <sub>2</sub> subtypes.

		Age (yr)	Reciprocal antibody titer			
No	Field Isolates (Shiraz)		Α	В	С	D
1	A/Shiraz/1/2005 (H1N1)	5	64	<1	<1	<1
2	A/Shiraz/2/2005 (H <sub>1</sub> N <sub>1</sub> )	6	64	<1	<1	<1
3	A/Shiraz/3/2005 (H <sub>1</sub> N <sub>1</sub> )	5	64	<1	<1	<1
4	A/Shiraz/4/2005 (H <sub>1</sub> N <sub>1</sub> )	10	64	<1	<1	<1
5	A/Shiraz/5/2005 (H <sub>3</sub> N <sub>2</sub> )	2	<1	4	<1	<1
6	A/Shiraz/6/2005 (H <sub>3</sub> N <sub>2</sub> )	3	<1	8	<1	<1
7	A/Shiraz/7/2005 (H <sub>3</sub> N <sub>2</sub> )	5	<1	8	<1	<1
8	A/Shiraz/8/2005 (H <sub>3</sub> N <sub>2</sub> )	11	<1	4	<1	<1
9	A/Shiraz/9/2005 (H <sub>3</sub> N <sub>2</sub> )	2	<1	4	<1	<1
10	A/Shiraz/10/2005 (H <sub>3</sub> N <sub>2</sub> )	3	<1	8	<1	<1

A= A/NewCaledonia/20/99 (H<sub>1</sub>N<sub>1</sub>)-like; B= A/Moscow 10/99 (H<sub>3</sub>N<sub>2</sub>); C= B/Sichuan 330/2001-like; D= B/Hong Kong 330/2001-like

isolated from children of older age (Table 2).  $A/H_3N_2$  isolate appears to be antigenically different from corresponding reference antigen. This is evident by a 16-fold reduction in antibody titer against  $A/H_3N_2$  Isolate (1:8), as compared to that of reference antigen (1:128).

#### Discussion

The present study describes the first attempt to isolate influenza viruses from pharyngeal specimens during winter outbreak in Fars province south of Iran. Serotyping by standard reference antisera showed that at least 10 of 31 hemagglutinating viruses tested, were either  $H_1N_1$  or  $H_3N_2$  influenza subtypes. Undoubtedly, the remaining isolates were likely other respiratory viruses. In connection with the results obtained,  $H_3N_2$  strain was more frequently isolated from younger children, aged from 18 months to 5 years, whereas  $H_1N_1$  subtype was mostly isolated from those aged from 5 to 10 years.

A review of influenza infection in the Netherlands showed a varying seasonal incidence of 46% among children from few months zero to 19 years with an overall incidence of 5% to 9.5% per yr.<sup>8</sup> In this context, more than 50% of  $H_1N_1$  infection was reported to occur among subjects aged 10-34 years.<sup>9</sup> This was in accord with the results of the present investigation in which  $H_1N_1$  subtype prevailed among children of older age (Table 2).

According to an update of influenza virus activity during the 2004-5 influenza seasons, influenza  $A/H_3N_2$ , but not  $A/H_1N_1$  subtype, was isolated from Iran and several Asian countries.<sup>3</sup> It is noteworthy that the present study reported the isolation of influenza  $(H_1N_1)$  subtype from southern Iran. On the basis of the results obtained, the outbreak due to  $H_1N_1$  subtype preceded the emergence of  $H_3N_2$  outbreak and was of short duration, a finding consistent with low level circulation of  $H_1N_1$  in most parts of the world.<sup>4</sup>

Interestingly, the reciprocal antibody titer of reference antiserum against  $A/H_{\rm 3}N_{\rm 2}$  isolate

was 16-fold lower than the homologous titer (Table 2). In this regard, the antigenic drift in HA molecule of A/H<sub>3</sub>N<sub>2</sub> isolated may account for the low titer of reference antibody against this subtype.<sup>10-14</sup> This was supported by a continuous drift of A/H<sub>3</sub>N<sub>2</sub> strain reported during 2004 outbreak in Nepal.<sup>15</sup> This finding might warrant the reappraisal of current influenza vaccine. This was consistent with the study performed in New Caledonia, where identification of circulating viral types was carried out to gather information for the local vaccination program.<sup>16</sup> In this connection, the isolation of  $H_3N_2$  subtypes in the present study may suggest that the current influenza vaccine may not be sufficiently protective against influenza outbreaks caused by this subtypes." but the final identification awaits further antigenic analysis and molecular studies.

#### Conclusion

In the light of antigenic difference of  $A/H_3N_2$  shown in the present investigation, currently used influenza vaccine is not suitable for vaccination in southern Iran and needs to be reappraised.

## Acknowledgements

This work was financially supported by a grant (84-2399) from Vice Chancellor for Research, Shiraz University of Medical Sciences. The authors would like thank Pedram Talaezadeh and Mojgan Noorouzbabaei for their valuable technical assistance.

#### References

- 1 Turner JL, Fielding JE, Clothier HJ, Kelly HA. Influenza surveillance in Victoria, 2005. *Commun Dis Intell* 2006; 30: 137-43.
- 2 Ansaldi F, D'agaro P, Burgnich P, et al. Three-year (1999-2002) of epidemiological and virological surveillance of influenza in north-east Italy. *Eur J Epidemiol* 2004; 19: 885-90.

A. Moattari, M.R. Kadivar, T. Mokhtari Azad

- 3 Pabarijaona LP, Rakotondrarija NT, Rousset D, et al. Influenza epidemiologic and virologic surveillance in Antananarivo from 1995 to 2002. *Arch Inst Pasteur Madagascar* 2003; 69: 20-6.
- 4 Centers for Disease Control and Prevention (CDC). Update: Influenza activityunited states and worldwide, 2004-05 season. *MMWR Morb Mortal Wkly Rep* 2005; 54: 631-4.
- 5 Blanc P, Noel G, Dubus JC, Garnier JM. Pediatric features of influenza A seasonal outbreak and its burden in pediatric emergency rooms and pediatric departments. *Arch Pediatr* 2006; 13: 11-6.
- 6 Hay AJ, Gregory V, Douglas AR, Lin YP. The evolution of human influenza viruses. *Philos Trans R Soc Lond B Biol Sci* 2001; 356: 1861-70.
- 7 Couch RB, Kasel JA. Influenza. In: Lennett EH, Lennett DA, Lennett ET eds: Diagnostic procedures for viral, Rickettsial, and chlamydial infections 7<sup>th</sup> ed Washington DC American Public health association; 1995. p. 431-46.
- 8 Bueving HJ, Van der wooden JC, Berger MY, Thomas S. Incidence of influenza and associated illness in children aged 0-19 years: asystematic review. *Rev Med virol* 2005; 15: 383-91.
- 9 Glezen WP, Keitel WA, Taber LH, et al. Age distribution of patients with medically-

attended illnesses caused by sequential variants of influenza A/H<sub>1</sub>N<sub>1</sub>: Comparison to Age-specific infection rates, 1978-1989. *Am J Epidemiol* 1991; 133: 296-304.

- 10 Kitler ME, Gavinio P, Lavanchy D. Influenza and the work of the World Health Organization. *Vaccin* 2002; 2: S5-14.
- 11 Six HR, Webster RG, Kendal AP. Antigenic analysis of H<sub>1</sub>N<sub>1</sub> viruses isolated in the Houston metropolitan area during successive seasons. *Infect Immun* 1983; 42: 453-8.
- 12 Stevens DJ, Douglas AR, Skehel JJ, Wiley DC. Antigenic and amino acid sequence analysis of the variants of H<sub>1</sub>N<sub>1</sub> influenza virus in 1986. *Bull World Health Organ* 1987; 65: 177-80.
- 13 Natali A, Oxford JS, Schild GC. Frequency of naturally occurring antibody to influenza virus antigenic variants selected in vitro with monoclonal antibody. *J Hyg (Lond)* 1981; 87: 185-90.
- 14 Wang ML, Skehel JJ, Wiley DC. Comparative analyses of the specificities of antiinfluenza hemagglutinin antibodies in human sera. *J virol* 1986; 57: 124-8.
- 15 Daum LT, Shaw MW, Klimov AI, et al. Influenza A (H<sub>3</sub>N<sub>2</sub>) outbreak, Nepal. *Emerg Infect Dis* 2005; 11: 1186-91.
- 16 Berlioz-Arthaud A, Barr IG. Laboratorybased influenza surveillance in New Caledonia, 1999-2003. *Trans R Soc Trop Med Hyg* 2005; 99: 290-300.